Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Neurosteroids for Treatment of PTSD in Veterans

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
Durham (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
97 fő vett részt
Kezdés
2019. jún. 27.
Befejezés
2025. júl. 14.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Pregnenolone
  • Placebo
A regiszteradat frissítve
2026. augusztus 26.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • At study outset: DSM-5 diagnosis of PTSD with CAPS-5 Total Score >=30. Following protocol amendment effective 4/13/2023: criterion modified to require diagnosis of PTSD using the CAPS-5 definition, defined by the following: at least one Criterion B symptom, at least one Criterion C symptom, at least 2 Criterion D symptoms and at least 2 Criterion E symptoms. This thus replaced the firm cutoff of CAPS-5 Total Score >=30
  • Females will be required to use a medically and study approved contraceptive or otherwise not be of child-bearing potential; Birth control methods must be non-hormonal
  • No anticipated need to alter psychiatric medications for duration of study involvement
  • Ability to participate fully in the informed consent process

Ki nem vehet részt

  • Current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern; Prior suicide attempt history or suicidal ideation that does not require clinical intervention or represent an imminent concern is permitted
  • Standard pharmacological interventions for PTSD will not be exclusionary, including, but not limited to:; antidepressant medications such as SSRIs, SNRIs, tricyclics, bupropion, mirtazapine, venlafaxine, and nefazodone; mood stabilizers such as carbamazepine, divalproex, lamotrigine, topiramate; atypical antipsychotics, and other agents including prazosin; However, there may be no changes in psychotropic medications for PTSD 4 weeks prior to study randomization
  • Initiation or change in psychotherapy within 3 months of randomization, i.e. psychotherapy must be stable for 3 months prior to study start
  • Participants on hormonal therapies such as finasteride or hormonal birth control
  • History of allergy to pregnenolone
  • Medical disorders that may preclude safe administration of pregnenolone or exacerbate PTSD symptoms
  • Serious unstable medical illness, such as:; history of cerebrovascular accident; prostate, uterine, or breast cancer; others (at the discretion of the PI and medical oversight team)
  • Medical conditions not well controlled will be excluded, at the discretion of the PI and Medical Team
  • Current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than mild TBI (assessed at screening)
  • As indicated by the DSM-5, moderate or severe Substance Use Disorders (excluding caffeine and tobacco) within 1 month of study entry; Mild Alcohol Use Disorder is not exclusionary, at the judgment of the PI and her medical team
  • Benzodiazepine use
  • Female participants who are pregnant or breast-feeding

Helyszínek itt: Egyesült Államok

  • Durham VA Medical Center, Durham, NCDurham, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study seeks to determine if pregnenolone can improve symptoms of PTSD and other symptoms that commonly occur with PTSD in Iraq/Afghanistan-era Veterans. The total study duration for each participant is 10 weeks. Eligible Veterans with PTSD will receive either pregnenolone or placebo throughout the study duration and will complete mental and physical health assessments at each study visit. Eligible participants will attend 6 in-person study visits and receive several short "check-in" phone calls.

A vizsgálat 2 csoportja

  • PregnenoloneA vizsgált kezelés

    Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial

  • PlaceboPlacebo, összehasonlításként

    Matching placebo medication dispensed identically with the same number and frequency as the experimental arm

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
A regiszteradat frissítve
2026. augusztus 26.